Please wait while your page loads ...

How to apply for a FARA Research Grant

FARA accepts LOIs from investigators from public and private nonprofit universities, colleges, hospitals, laboratories, government agencies, biotechnology/pharmaceutical companies, other for-profit entities; irrespective of the country of origin. FARA particularly encourages junior investigators to submit LOIs. Junior investigators and postdoctoral trainees who would like support through the application process or general advice on grant writing may contact FARA at

FARA-funded research has accelerated the development of clinical and pre-clinical research resources such as animal models, cell models, antibodies, biorepositories, biomarkers and clinical endpoints. Our goal is to facilitate access to such resources and promote collaboration among FA investigators. Please see for more information on how to access available research resources in FA.

Overview of Grant Program Process

+ Letter Of Intent
All LOIs must be submitted using FARA's grant submission portal. The LOI must explain how the proposed research addresses FARA’s grant program priorities. This is a competitive, peer-review process, as such only a small number of applications are accepted past the LOI phase. The LOI should be sufficiently detailed to allow the reader to understand the validity and applicability of the project. This decision will usually be made within a month of receipt of the LOI. LOIs are accepted from forprofit organizations, non-profit organizations, public or private institutions, and foreign institutions. Please note the grant funding start dates for each cycle here and select your submission cycle accordingly.
+ Application All applications must be submitted using FARA's grant submission portal. This includes a lay summary of the project, budget and a timeline with detailed milestones. The project description, curriculum vitae/biosketch of each of the key investigators, letters of support, and other relevant documents must be submitted as PDF files.
+ Award for Innovative Mindset AIM grants do not require an LOI. Please submit your AIM proposal using the LOI submission form in FARA's grant submission portal.
+ Review and Decision Process All grant applications submitted to FARA undergo a rigorous and confidential review procedure that is overseen by the FARA Scientific Review Committee (SRC).
+ Reporting Requirements All FARA grantees must submit annual scientific and financial reports using FARA's grant submission portal. For Graduate Research Fellowships, a yearly statement of continuing support by the mentor is also required. The required frequency of reports will be stated in the formal funding agreement with FARA. Each report must be submitted to the portal as a PDF file.

Continuation funding will not be provided until all required progress reports are received and reviewed by the FARA SRC, and approved for funding by the FARA Executive Committee.
Any rebudgeting of funds requires prior FARA approval. Please submit rebudgeting requests by email at indicating the amount to be rebudgeted, spending categories involved and an explanation of why the rebudgeting is needed.
FARA also encourages investigators to present their FARA funded research at least once during the course of their grant at the FARA Forum, on a mutually agreed upon date. The Forum is a monthly webinar open to FARA grant awardees and the FARA Scientific Advisory Board and it is held on the second Tuesday of every month.
+ General Policies Click here to learn more about FARA's general policies for research grants.
+ General Guidelines for Junior Investigators Click here to learn more about FARA's general guidelines for junior investigators applying for FARA research grants.
+ General Guidelines for Industry Click here to learn more about FARA's general guidelines for Industry (Biopharmaceutical Companies) applying for FARA research grants.


Grant program updates and announcements

View special interest RFPs and other grant program updates and announcements here.

Newly awarded grants

Gene & Stem Cell Therapy​

Joseph Nabhan, PhD - Vesigen Therapeutics, Cambridge (MA)
Evaluation of ARMMs-mediated delivery of Cas9 protein complexed with gRNAs as a non-viral disease-modifying strategy for Friedreich’s ataxia

Changfan Lin, PhD - Caltech
Engineering adeno-associated viral vectors to evade immune responses

Mechanism or Pathway of Disease​

Pei-Yu Chen, PhD - Yale University
TGFβ signaling activity as disease biomarkers and therapeutic targets in Friedreich’s Ataxia

Sarah Robinson-Thiewes, PhD - St. Jude Children’s Research Hospital
Illuminating how SynGRs liberate gene expression from heterochromatin

Anna Stepanova, PhD - Weill Cornell Medical College
Calcium communication among intracellular compartments in FA patient-derived cells

Outcome Measures & Biomarkers

David Lynch, MD, PhD, Wiliam Gaetz, PhD & Timothy Roberts, PhD - Children’s Hospital of Philadelphia
Imaging of glutathione and GABA in the brain as biomarkers of Friedreich Ataxia

Louise Corben, PhD - Murdoch Children’s Research Institute
Measuring ataxia in children with Friedreich ataxia

Cardiac Research

Laura Kropp, PhD, MPH - Stealth BioTherapeutics
Advancing novel mitochondrial therapies for FA cardiomyopathy: a pragmatic collaboration to move new therapies forward

Are you subscribed to our science newsletter, Friedreich's ataxia Community Research News?
If you are not a subscriber, please click here to sign-up!
Privacy Policy      Service Terms      Contact      Charity Navigator